U.S. Physical Therapy (USPH) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
U.S. Physical Therapy (USPH) has outperformed GeneDx (WGS) over the past year, gaining 33.9% versus a loss of 69.0%. Over five years, USPH leads with a +8.3% price change compared with -80.0% for WGS. U.S. Physical Therapy is the larger company by market cap ($1.43 billion vs $1.36 billion), about 1.1 times the size, while GeneDx is growing revenue faster (+40.0% vs +16.3%).
On valuation, U.S. Physical Therapy trades at a lower forward P/E (28.5x vs 34.9x for GeneDx). U.S. Physical Therapy pays a dividend yielding 1.91%, while GeneDx does not currently pay one. U.S. Physical Therapy converts more of its revenue into profit, with a net margin of 5.1% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | USPH | WGS |
|---|---|---|
| Share price | $95.93 | $45.46 |
| Market cap | $1.43B | $1.36B |
| 1-day change | +1.71% | -7.68% |
| YTD return | +22.85% | -65.05% |
| 1-year return | +33.92% | -68.98% |
| 5-year return | +8.32% | -80.01% |
| Forward P/E | 28.50 | 34.93 |
| EPS (TTM) | $-1.33 | $-3.76 |
| Dividend yield | 1.91% | 0.00% |
| Annual dividend | $1.83 | $0.00 |
| Revenue (latest FY) | $780.99M | $427.54M |
| Revenue growth (YoY) | +16.33% | +39.97% |
| Net income (latest FY) | $39.58M | $-21.02M |
| Gross margin | 19.17% | 69.74% |
| Operating margin | 11.10% | -3.06% |
| Net margin | 5.07% | -4.92% |
| 52-week high | $101.80 | $170.87 |
| 52-week low | $58.19 | $32.21 |
| Distance from 52-week high | -5.77% | -73.39% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +16.23% | +80.38% |
| Average volume | 186.22K | 869.34K |
| Shares outstanding | 14.93M | 29.97M |
| Employees | 4,653 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- USPH has outperformed WGS by 102.9 percentage points over the past year.
- U.S. Physical Therapy offers a meaningfully higher dividend yield (1.91% vs 0.00%).
- U.S. Physical Therapy is more profitable, keeping 5.1 cents of every revenue dollar as net income versus -4.9 cents for GeneDx.
- GeneDx grew revenue faster in its latest fiscal year (+39.97% vs +16.33%).
About U.S. Physical Therapy
USPH stock →U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics.
Health Care · Medical/Nursing Services · 4,653 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
USPH vs WGS FAQ
Which is bigger, U.S. Physical Therapy or GeneDx?
U.S. Physical Therapy (USPH) is larger, with a market capitalization of $1.43B compared with $1.36B for GeneDx (WGS).
Which stock has performed better over the past year, USPH or WGS?
USPH returned +33.92% over the past 12 months, compared with -68.98% for WGS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, U.S. Physical Therapy or GeneDx?
U.S. Physical Therapy pays a dividend yielding 1.91%, while GeneDx does not currently pay a regular dividend.
Are U.S. Physical Therapy and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.